Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SI | P14410 | 1/20 | 0.52 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL460011 | 0.89 | MGAM (0.46) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL19105326 | 0.87 | MGAM (0.44) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL4661806 | 0.87 | MGAM (0.44) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL11565070 | 0.87 | ALOX15 (0.44) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL4529653 | 0.87 | MGAM (0.44) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL19105350 | 0.86 | GAA (0.54) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL8917503 | 0.85 | ALDH1A1 (0.54) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL25181738 | 0.85 | MGAM (0.43) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL6974108 | 0.85 | MGAM (0.43) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL10843736 | 0.83 | GAA (0.41) | MGAMGAASIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 371 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239042-A9 | IN-SITU REACTIVE CURING AND INFILTRATION IN BINDER JET ADDITIVE MANUFACTURING | U. S. DEPARTMENT OF ENERGY | 2024-07-18 | — | — | US | claimed |
| US-20240017484-A1 | IN-SITU REACTIVE CURING AND INFILTRATION IN BINDER JET ADDITIVE MANUFACTURING | UT BATTELLE LLC (US) | 2024-01-18 | — | — | US | claimed |
| US-10087383-B2 | Aviation fuel additive scavenger | AFTON CHEMICAL CORPORATION (US) | 2018-10-02 | — | — | US | claimed |
| US-20170283728-A1 | AVIATION FUEL ADDITIVE SCAVENGER | AFTON CHEMICAL CORPORATION | 2017-10-05 | — | — | US | claimed |
| EP-3225681-A1 | AVIATION FUEL ADDITIVE SCAVENGER | Afton Chemical Corporation (US) | 2017-10-04 | — | — | EP | claimed |
| US-5795447-A | Separation of 2-butanol from isobutanol by extractive distillation | BERG LLOYD (US) | 1998-08-18 | — | — | US | claimed |
| EP-4013749-B1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12565000-B2 | In-situ reactive curing and infiltration in binder jet additive manufacturing | UT-BATTELLE, LLC (US) | 2026-03-03 | — | — | US | disclosed |
| US-20260049063-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260001838-A1 | NANOMATERIALS | GUIDE THERAPEUTICS LLC (US) | 2026-01-01 | — | — | US | disclosed |
| US-12448492-B2 | Organic polymer aerogels comprising microstructures | Blueshift Materials, Inc. (US) | 2025-10-21 | — | — | US | disclosed |
| US-12435035-B2 | Nanomaterials | GUIDE THERAPEUTICS, LLC (US) | 2025-10-07 | — | — | US | disclosed |
| US-12435046-B2 | Alkynyl quinazoline compounds | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-4143160-A | COSMETIC CONTAINING POLYCARBOXYLIC ACIDS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1979-03-06 | — | — | US | disclosed |
| US-4142046-A | BACTERICIDES, 7-AMINO-CEPHALOSPORINS | SMITHKLINE CORPORATION (US) | 1979-02-27 | — | — | US | disclosed |
| US-4076601-A | FROM DIMETHYL MALONATE | MONSANTO COMPANY (US) | 1978-02-28 | — | — | US | disclosed |
| US-4060610-A | Pharmaceutical compositions comprising 7-acyl-3-(substituted triazolyl thiomethyl)-cephalosporins and methods of treating bacterial infections | SMITHKLINE CORPORATION (US) | 1977-11-29 | — | — | US | disclosed |
| US-3989694-A | ANTIBACTERIAL | SMITHKLINE CORPORATION (US) | 1976-11-02 | — | — | US | disclosed |
| US-3974165-A | Hypotensive agents | BRISTOL-MYERS COMPANY (US) | 1976-08-10 | — | — | US | disclosed |
| US-3959263-A | Prostaglandin intermediate | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435046-B2 | Alkynyl quinazoline compounds | GLS, GLS2, MCL1 | MGAM 4821/4885GAA 330/4885SI 1752/4885 |
| US-20260001838-A1 | NANOMATERIALS | SLC10A1, NPC1L1, FABP1 | MGAM 4788/4885GAA 3451/4885SI 3661/4885 |
| US-12435035-B2 | Nanomaterials | NPC1, NPC1L1, FABP1 | MGAM 4599/4885GAA 1479/4885SI 3839/4885 |
| US-12565000-B2 | In-situ reactive curing and infiltration in binder jet additive manufacturing | BHMT, TST, TMT1A | MGAM 693/4885GAA 4296/4885SI 1844/4885 |
| US-20260049063-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, BCL6 | MGAM 4777/4885GAA 719/4885SI 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.